What were the clinical success rates according to pathogen?
|Individual pathogens identified by culture or serology revealed the most common respiratory pathogen to be S. pneumoniae, with 750 mg and 500 mg levofloxacin regimens achieving a 90.9% and 90.0% clinical success rate, respectively (Table 4). The most common atypical pathogen identified was M. pneumoniae, and the clinical success rates in patients infected with this pathogen were 95.3% for the 750 mg group and 94.4% for the 500 mg group.|
Table 4. Levofloxacin 750 mg q.d. for 5 days for CAP: clinical success by pathogen a
|Source/pathogen||n/N (%) of patients b
|Levofloxacin 750 mg
q.d. for 5 days
|Levofloxacin 500 mg
q.d. for 10 days
|Respiratory cultures (typical pathogens)|
|Haemophilus influenzae||12/13 (92.3)||13/14 (92.9)|
|Haemophilus parainfluenzae||12/12 (100)||9/10 (90.0)|
|Streptococcus pneumoniae||20/22 (90.9)||18/20 (90.0)|
|Serologies (atypical pathogens)|
|Chlamydia pneumoniae||20/22 (90.9)||16/16 (100)|
|Legionella pneumophila||11/11 (100)||3/3 (100)|
|Mycoplasma pneumoniae||41/43 (95.3)||34/36 (94.4)|
|a||Identified in at least 5 clinically evaluable patients at the 7- to 14-day post-therapy visit. Clinical success includes cured and improved.|
|b||Numbers shown in parentheses are percentages of patients infected with the pathogen who had a clinical response of cure or improvement divided by total number of patients infected with the pathogen.|
Abbreviations: CAP = community-acquired pneumonia, q.d. = once daily.
Adapted from reference (50).